Baxter Sells its BioPharma Solutions Business for $4.25 Billion

Baxter International has signed an agreement to divest its BioPharma Solutions business to investors Advent International and Warburg Pincus for $4.25 billion.

The divestiture further streamlines Baxter’s strategic focus and represents an important milestone in its ongoing business transformation, the company said.

The proceeds from the transaction, which is expected to close in the second half of 2023, will be used to reduce Baxter’s debt.

BioPharma Solutions provides sterile contract manufacturing solutions, parenteral delivery systems and customized support services to the pharma and biotech industries.

Related Topics